A Single-Dose, Dose Escalation, Safety, Tolerability, and Pharmacokinetic Study of LY3050258
Latest Information Update: 03 Sep 2018
At a glance
- Drugs LY 3050258 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 16 Dec 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Nov 2013 New trial record